The system to malignant tumor treatment diverges significantly between the America and Continental Europe . In the United States, receiving care is often linked to private coverage , leading in possibly substantial costs and inconsistent outcomes . Unlike, Continental healthcare generally offer broad access through government-funded supported well-

While both the United States and Europe strive to provide optimal cancer care, their systems differ significantly. The US often emphasizes innovative treatments, sometimes leading to greater costs. In contrast, European systems tend to prioritize preventive care and affordability, highlighting early diagnosis. This can result in distinct patient ex